Diasorin SpA (CHIX:DIAm)
€ 91.5 (0%) Market Cap: 4.90 Bil Enterprise Value: 5.58 Bil PE Ratio: 26.50 PB Ratio: 2.94 GF Score: 91/100
Back to the Transcripts List

Q1 2025 DiaSorin SpA Earnings Call Transcript

May 6, 2025 / 04:00 PM GMT
Release Date Price: €97.98

Key Points

Positve
  • Diasorin SpA (WBO:DIAS) reported a 7% revenue growth in Q1 2025 compared to Q1 2024, with a strong performance in both immuno and molecular diagnostics.
  • The company's COVID-related revenue was in line with guidance, contributing €5 million in the quarter.
  • North America showed significant growth with an 18% increase, driven by the success of the US hospital strategy.
  • The molecular diagnostics segment, excluding COVID, grew by 7%, with multiplexing showing a 25% increase.
  • The company confirmed its full-year guidance of 8% revenue growth and a 34% EBITDA margin, indicating confidence in its business strategy.
Negative
  • China remains a challenging market due to pricing pressures and competition from local players, impacting revenue growth.
  • The company faces potential FX headwinds due to USD/EUR fluctuations, which could affect revenue and EBITDA.
  • There is a noted impact from the discontinuation of the Ari platform, affecting molecular diagnostics growth.
  • Tariffs between the US and China could have a financial impact, although currently deemed negligible.
  • The immuno diagnostics segment in Europe showed slower growth compared to North America, reflecting market maturity and competitive pressures.


Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

DIAS.MI - DiaSorin SpA
Q1 2025 DiaSorin SpA Earnings Call
May 06, 2025 / 04:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good afternoon. This is the Chorus call conference operator. Welcome and thank you for joining the DSRN first quarter 2025 results conference call. As a reminder, all participants are in listen-only mode. After the presentation, there will be an opportunity to ask questions. Should anyone need assistance during the conference call, they may signal an operator by pressing star and 0 on the telephone.

At this time I would like to turn the conference over to Mr. Carlo Rosa, CEO of Diasorin. Please go ahead, sir.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Yes, thank you operator. Good
Already have an account? Log in
Get the full story
Start 7-Day Free Trial
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot
Research Tools
All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board
Product
Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文
Education
Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation
Company
About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program
Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey
Follow Us
download GuruFocus on Apple store download GuruFocus on Google Play
Disclaimers
GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.
© 2004-2025 GuruFocus.com, LLC. All Rights Reserved.